- Home
- TCRT vs LYRA Comparison
TCRT vs LYRA Comparison
Compare TCRT & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- LYRA
- Stock Information
- Founded
- TCRT 1998
- LYRA 2005
- Country
- TCRT United States
- LYRA United States
- Employees
- TCRT N/A
- LYRA N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- LYRA Medical/Dental Instruments
- Sector
- TCRT Health Care
- LYRA Health Care
- Exchange
- TCRT Nasdaq
- LYRA Nasdaq
- Market Cap
- TCRT 7.0M
- LYRA 7.6M
- IPO Year
- TCRT N/A
- LYRA 2020
- Fundamental
- Price
- TCRT $2.84
- LYRA $3.88
- Analyst Decision
- TCRT
- LYRA Hold
- Analyst Count
- TCRT 0
- LYRA 1
- Target Price
- TCRT N/A
- LYRA $16.00
- AVG Volume (30 Days)
- TCRT 40.3K
- LYRA 30.6K
- Earning Date
- TCRT 11-14-2025
- LYRA 11-12-2025
- Dividend Yield
- TCRT N/A
- LYRA N/A
- EPS Growth
- TCRT N/A
- LYRA N/A
- EPS
- TCRT N/A
- LYRA N/A
- Revenue
- TCRT $6,000.00
- LYRA $600,000.00
- Revenue This Year
- TCRT $5,680,500.00
- LYRA N/A
- Revenue Next Year
- TCRT N/A
- LYRA $106.28
- P/E Ratio
- TCRT N/A
- LYRA N/A
- Revenue Growth
- TCRT N/A
- LYRA N/A
- 52 Week Low
- TCRT $1.31
- LYRA $3.69
- 52 Week High
- TCRT $6.20
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- TCRT 57.03
- LYRA 22.62
- Support Level
- TCRT $2.69
- LYRA $5.40
- Resistance Level
- TCRT $3.15
- LYRA $4.80
- Average True Range (ATR)
- TCRT 0.22
- LYRA 0.42
- MACD
- TCRT 0.03
- LYRA -0.17
- Stochastic Oscillator
- TCRT 81.93
- LYRA 7.39
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.